FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094032739> ?p ?o ?g. }

• W3094032739 endingPage "S226" @default.
• W3094032739 startingPage "S226" @default.
• W3094032739 abstract "INTRODUCTION: Immune checkpoint inhibitors (ICIs) have shown practice-changing results in the treatment of many cancers, however, ICI-related gastrointestinal (GI) toxicity can limit their use. Upper GI toxicity is not as common nor as well described as lower GI toxicity. We aim to characterize esophagitis associated with ICIs by describing its clinical presentation, endoscopic features, histological findings, treatment response and outcomes. METHODS: This is a retrospective study of patients at a tertiary cancer center who developed esophagitis after receiving ICI between June 2011 and January 2020. The diagnosis of esophagitis was made based on esophagogastroduodenoscopy (EGD) findings. Patients with pre-existing gastro-esophageal disease, and recent head/neck/chest radiation were excluded. A χ2 test was used to determine associations between categorical variables. A Mann-Whitney U test was used to compare differences between continuous variables. RESULTS: Of the 657 consecutive patients who underwent EGD during or within 6 months of completing ICI therapy, 21 (3%) developed esophagitis of unclear etiology, which was deemed to be related to ICI. Of these patients, one (5%) received an inhibitor of cytotoxic T-lymphocyte associated antigen 4 alone, 15 (71%) received an inhibitor of programmed cell death protein 1 or its ligand alone, and 5 (24%) received a combination of the two classes (Table 1). The median time between the initiation of ICI and onset of esophagitis was 4 months. On EGD, isolated esophageal involvement was only seen in 3 patients (24%); distribution of esophagitis varied widely within the esophagus. Eighteen patients (86%) had concurrent involvement of the stomach, duodenum, or both. Histology showed signs of both acute and chronic inflammation (Figure 1). Proton pump inhibitors (PPIs) were used in 14 patients (67%). Steroids (prednisone or budesonide) were used in 4 patients (19%). Repeat endoscopy was only performed in 5 patients, 4 (75%) of which had complete resolution. There was a 38% mortality in our cohort during the study period (median follow up was 15 months) attributed to their underlying malignancy (Table 2). CONCLUSION: Esophagitis associated with ICI is rare. The diagnosis is one of exclusion since its clinical presentation appears similar to inflammation due to other causes. Symptoms are mild and respond well to non-immunosuppressive treatment with very few severe complications.Figure 1.: Endoscopic and histological features of ICI-related esophagitis. (A) Multiple large circumferential ulcers found in the middle third of the esophagus. (B) Inflammation noted in the gastro-esophageal junction (C) Non-bleeding erosions in the lower third of the esophagus. (D) Chronic active esophagitis, with increased neutrophils in squamous epithelium and lamina propria. Granulation tissue, clusters of lymphocytes and plasma cells in lamina propria (H&E, 20x). (E) Esophageal ulceration with underlying chronic active inflammation (H&E, 20x).Table 1.: Clinical information related to ICI and esophagitis (n = 21)Table 2.: Endoscopic findings, pathologic findings, treatment and outcomes (n = 21)" @default.
• W3094032739 created "2020-10-29" @default.
• W3094032739 creator A5003027125 @default.
• W3094032739 creator A5024797355 @default.
• W3094032739 creator A5026717218 @default.
• W3094032739 creator A5028479135 @default.
• W3094032739 creator A5039160380 @default.
• W3094032739 creator A5041940487 @default.
• W3094032739 creator A5042917768 @default.
• W3094032739 creator A5059350381 @default.
• W3094032739 creator A5064552246 @default.
• W3094032739 creator A5073007668 @default.
• W3094032739 creator A5078319904 @default.
• W3094032739 creator A5083071476 @default.
• W3094032739 date "2020-10-01" @default.
• W3094032739 modified "2023-09-27" @default.
• W3094032739 title "S0451 Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis" @default.
• W3094032739 doi "https://doi.org/10.14309/01.ajg.0000722228.79165.a2" @default.
• W3094032739 hasPublicationYear "2020" @default.
• W3094032739 type Work @default.
• W3094032739 sameAs 3094032739 @default.
• W3094032739 citedByCount "1" @default.
• W3094032739 countsByYear W30940327392021 @default.
• W3094032739 crossrefType "journal-article" @default.
• W3094032739 hasAuthorship W3094032739A5003027125 @default.
• W3094032739 hasAuthorship W3094032739A5024797355 @default.
• W3094032739 hasAuthorship W3094032739A5026717218 @default.
• W3094032739 hasAuthorship W3094032739A5028479135 @default.
• W3094032739 hasAuthorship W3094032739A5039160380 @default.
• W3094032739 hasAuthorship W3094032739A5041940487 @default.
• W3094032739 hasAuthorship W3094032739A5042917768 @default.
• W3094032739 hasAuthorship W3094032739A5059350381 @default.
• W3094032739 hasAuthorship W3094032739A5064552246 @default.
• W3094032739 hasAuthorship W3094032739A5073007668 @default.
• W3094032739 hasAuthorship W3094032739A5078319904 @default.
• W3094032739 hasAuthorship W3094032739A5083071476 @default.
• W3094032739 hasBestOaLocation W30940327391 @default.
• W3094032739 hasConcept C121608353 @default.
• W3094032739 hasConcept C126322002 @default.
• W3094032739 hasConcept C141071460 @default.
• W3094032739 hasConcept C167135981 @default.
• W3094032739 hasConcept C2777819096 @default.
• W3094032739 hasConcept C2778451229 @default.
• W3094032739 hasConcept C2779134260 @default.
• W3094032739 hasConcept C2779742542 @default.
• W3094032739 hasConcept C2779920096 @default.
• W3094032739 hasConcept C2781143854 @default.
• W3094032739 hasConcept C43270747 @default.
• W3094032739 hasConcept C71924100 @default.
• W3094032739 hasConcept C90924648 @default.
• W3094032739 hasConceptScore W3094032739C121608353 @default.
• W3094032739 hasConceptScore W3094032739C126322002 @default.
• W3094032739 hasConceptScore W3094032739C141071460 @default.
• W3094032739 hasConceptScore W3094032739C167135981 @default.
• W3094032739 hasConceptScore W3094032739C2777819096 @default.
• W3094032739 hasConceptScore W3094032739C2778451229 @default.
• W3094032739 hasConceptScore W3094032739C2779134260 @default.
• W3094032739 hasConceptScore W3094032739C2779742542 @default.
• W3094032739 hasConceptScore W3094032739C2779920096 @default.
• W3094032739 hasConceptScore W3094032739C2781143854 @default.
• W3094032739 hasConceptScore W3094032739C43270747 @default.
• W3094032739 hasConceptScore W3094032739C71924100 @default.
• W3094032739 hasConceptScore W3094032739C90924648 @default.
• W3094032739 hasIssue "1" @default.
• W3094032739 hasLocation W30940327391 @default.
• W3094032739 hasLocation W30940327392 @default.
• W3094032739 hasOpenAccess W3094032739 @default.
• W3094032739 hasPrimaryLocation W30940327391 @default.
• W3094032739 hasRelatedWork W14432231 @default.
• W3094032739 hasRelatedWork W1905853318 @default.
• W3094032739 hasRelatedWork W1967957440 @default.
• W3094032739 hasRelatedWork W1975266600 @default.
• W3094032739 hasRelatedWork W2010771602 @default.
• W3094032739 hasRelatedWork W2053036048 @default.
• W3094032739 hasRelatedWork W2056156526 @default.
• W3094032739 hasRelatedWork W2163889944 @default.
• W3094032739 hasRelatedWork W2411319260 @default.
• W3094032739 hasRelatedWork W3030235090 @default.
• W3094032739 hasVolume "115" @default.
• W3094032739 isParatext "false" @default.
• W3094032739 isRetracted "false" @default.
• W3094032739 magId "3094032739" @default.
• W3094032739 workType "article" @default.